Figure 2
Figure 2. PK for subjects with specific pretreatment nonneutralizing anti-VWF–binding antibodies. Subject #21: (A) VWF:Ag after pdVWF-FVIII infusion, (B) VWF:Ag after rVWF-rFVIII infusion, (C) VWF:RCo after rVWF-rFVIII infusion, and (D) FVIII:C after rVWF-rFVIII infusion. Subject #23: (E) VWF:Ag after rVWF-rFVIII infusion, (F) VWF:RCo after rVWF-rFVIII infusion, and (G) FVIII:C after rVWF-rFVIII infusion.

PK for subjects with specific pretreatment nonneutralizing anti-VWF–binding antibodies. Subject #21: (A) VWF:Ag after pdVWF-FVIII infusion, (B) VWF:Ag after rVWF-rFVIII infusion, (C) VWF:RCo after rVWF-rFVIII infusion, and (D) FVIII:C after rVWF-rFVIII infusion. Subject #23: (E) VWF:Ag after rVWF-rFVIII infusion, (F) VWF:RCo after rVWF-rFVIII infusion, and (G) FVIII:C after rVWF-rFVIII infusion.

Close Modal

or Create an Account

Close Modal
Close Modal